Rezolute (NASDAQ:RZLT) Stock Rating Lowered by Wall Street Zen

Rezolute (NASDAQ:RZLT) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday.

Several other equities analysts also recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Rezolute in a report on Tuesday, April 21st. Maxim Group boosted their price target on Rezolute from $10.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Citigroup upgraded Rezolute from a “market perform” rating to an “outperform” rating in a research note on Wednesday, June 3rd. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Rezolute in a research note on Tuesday, June 2nd. Finally, BTIG Research upped their price objective on Rezolute from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8.75.

Rezolute Stock Performance

Shares of RZLT stock opened at $4.00 on Friday. The firm has a market cap of $385.16 million, a P/E ratio of -4.88 and a beta of 0.68. Rezolute has a fifty-two week low of $1.07 and a fifty-two week high of $11.46. The business’s 50 day moving average price is $3.46 and its 200-day moving average price is $3.68.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. As a group, equities analysts predict that Rezolute will post -0.69 EPS for the current year.

Institutional Investors Weigh In On Rezolute

Institutional investors and hedge funds have recently modified their holdings of the business. Mangrove Partners IM LLC increased its holdings in shares of Rezolute by 25.4% in the 3rd quarter. Mangrove Partners IM LLC now owns 2,882,149 shares of the company’s stock valued at $27,092,000 after acquiring an additional 584,660 shares during the period. 22NW LP bought a new position in shares of Rezolute in the 3rd quarter worth $7,714,000. Caxton Corp raised its position in shares of Rezolute by 23.9% in the 3rd quarter. Caxton Corp now owns 1,986,818 shares of the company’s stock worth $18,676,000 after acquiring an additional 382,832 shares in the last quarter. Integral Health Asset Management LLC raised its position in shares of Rezolute by 11.1% in the 3rd quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock worth $18,800,000 after acquiring an additional 200,000 shares in the last quarter. Finally, Knott David M Jr bought a new position in shares of Rezolute in the 3rd quarter worth $2,585,000. 82.97% of the stock is owned by institutional investors.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.